Greater London, England, United Kingdom
Currently Chair of MNI Markets (Tenzing) and Prenax (Triton). Previously Chair of Chambers and Partners (Inflexion), Third Bridge (IK Investment Partners) and NED at Evaluate Pharma (HG Capital). I love working in non exec roles either to partner founders as they grow and eventually transition their businesses to new owners or with new owners to drive transformation in previously founder-led businesses. Previously B2B Publishing entrepreneur who invested in (as a start up) and then joined the Founders of Mergermarket in 2001. A five year period of rapid growth led to a sale to the Financial Times in 2006 and continued expansion post earnout.
Procurement & management of subscription-based resources
MNI is the leading provider of news and intelligence specifically for the Global Foreign Exchange and Fixed Income Markets, providing timely, relevant, and critical insight for market professionals and those who want to make informed investment decisions. Founded in 1983, MNI has press credentials recognised by both US houses of Congress, the Fed, the Bundesbank, the ECB, as well as by the governments and central banks of the G7 + China. MNI has bureaus across Europe, Asia and the United States. To learn more, please visit www.marketnews.com.
Researching outstanding lawyers globally. At Chambers, we make it our mission to empower the legal profession with the world’s most trusted research and intelligence. https://chambers.com/overview/
Third Bridge provides private equity firms, hedge funds and strategy consultants with the information that they need to understand the value of their investment opportunities. Our vision for delivering deep insight and unbiased market intelligence has evolved into a business with a range of complementary services, five offices across three continents and a global client base. Whether it is facilitating a private conversation with an industry veteran, moderating a dialogue between experts and investors, or extracting insights from within the supply chain of a poorly documented industry, we are on our clients’ side, helping them to make informed investment decisions. Prior to December 2015, Third Bridge was known as Cognolink.
EvaluatePharma is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2022 for commercial teams and their advisors within the global life science industry. We help our clients make high value decisions through superior quality, timely, must-have data, insights, combined with personalised, expert client support. Our online subscription services cover the pharmaceutical, biotech and medtech sectors. Our Custom Services group delivers project based analytical and data services. Vantage, our independent, award-winning editorial team, offers data-driven, forward-looking news, commentary and analysis on a daily basis. For more information visit www.evaluate.com. On Twitter: @Evaluatepharma, @EPVantage